MAGE-A3 vaccine

N/A

Report date: 2026/05/25 20:02:40

Base Information

Drug NameMAGE-A3 vaccine
Drug Alias NameBiropepimut-SMAGE-A3 Trojan Peptide Vaccine6XJF4EZC5Z (UNII code)GL-0817
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Synthetic peptide vaccine
Mechanisms of ActionImmunomodulatorsMelanoma-associated antigen 3 modulators
TargetsMelanoma-associated antigen 3
Therapy Area/IndicationsOral Squamous Cell CarcinomaMultiple MyelomaSquamous Cell Carcinoma of Head and Neck
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUkrainePoland +[7] 
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMayo ClinicUniversity Of Maryland
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of Maryland, BaltimoreGliknik IncUniversity of Arkansas
Active IndicationsN/A
Inactive IndicationsOral Squamous Cell CarcinomaMultiple MyelomaSquamous Cell Carcinoma of Head and Neck

Other Information

ATC CodeN/A
Related LinksN/A